KLK3 and prostate cancer: The Prostate Cancer Working Group 3 (PCWG3) defines progression based on three criteria: biochemical [prostate-specific antigen (PSA) increase ≥ 25% and ≥ 2 ng/mL above nadir], radiographic (per RECIST criteria), or clinical (worsening pain or quality of life)[10].